

PRESS RELEASE | ECULLY, FRANCE - May 31, 2021

Seqens participated in the 3rd Franco-German Technology Dialogue on the resilience of European healthcare industries held today under the chairmanship of Chancellor Angela Merkel, President Emmanuel Macron and President Ursula Von der Leyen.

On May 31, 2021, alongside 10 other major industrialists in the sector, Seqens participated in the 3rd Franco-German Technology Dialogue under the presidency of Chancellor Angela Merkel, President Emmanuel Macron and President Ursula Von der Leyen dedicated to "strengthening the resilience of the European medical and pharmaceutical industry" and on the role of innovation in production processes to accelerate the energy transition by maintaining a competitive and sustainable European industry.

Seqens had the opportunity to highlight its capacity for innovation and the very significant investments made over the last ten years in our European industrial base, both in terms of R&D capacity and new production capacity, which have enabled us to maintain and develop activities that are absolutely essential for our sector, throughout the value chain.

It was also an opportunity to review the strong mobilization of Seqens' teams since the beginning of the health crisis, and throughout the world, to ensure the production of certain critical products in shortage on the European territory. On the strength of this commitment, Seqens has also mobilized its know-how and innovation capacities to launch, with the support of the Recovery Plans :

- Industrialization projects to enable the competitive and environmentally friendly production of essential molecules in Europe;
- Accelerated R&D and industrialization of new processes, particularly for molecules to treat covid-19 ;
- Improving the efficacy of new vaccines and treatments with products that improve bioavailability. These are for example lipids or polymers for the vectorization of nucleic acids

During these exchanges, Seqens mentioned the main lines of action to ensure European health sovereignty over its businesses and guarantee the resilience of our value chains:

- To support the investments of European industrialists in the relocation of critical technologies for the production of essential molecules;
- To support innovation aimed at the faster industrialization of new technologies that are more efficient, more competitive and more environmentally friendly;
- Protect our industries from social and environmental dumping and guarantee a minimum production in Europe;
- Review drug purchasing and pricing strategies to take into account such important criteria as security of supply and environmental friendliness;

"We are convinced that our industry has a key role to play in ensuring our health sovereignty and in supporting the development of new pharmaceutical treatments over the long term. Seqens and other innovative companies in the sector are essential links in the chain and are ready to take up the challenge." says Pierre Luzeau, President of SEQENS.

www.seqens.com



About SEQENS:

Seqens is an integrated leader in the development and production of active ingredients, pharmaceutical intermediates and specialty ingredients. With a turnover of more than 1 billion euros, a presence in Europe, North America and Asia, 24 production sites, 7 R&D centers and 3,200 employees, Seqens is one of the European leaders in the sector.

As an integrated player across the value chain - from raw materials to active ingredients and from research and development to industrialization - SEQENS offers a broad portfolio of active ingredients, pharmaceutical intermediates and specialty ingredients, develops and industrializes the most demanding molecules under contract, and relies on its ability to innovate, develop and implement the best available technologies.

Driven by a culture of excellence and a strong entrepreneurial spirit, our 3,200 employees are committed to providing our customers with the highest level of service and quality while acting ethically in accordance with our corporate social responsibility program.

press@seqens.com / www.seqens.com / [Linkedin](#) : SEQENS / [Twitter](#) : seqens_group